Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.08 EUR
Change Today -0.001 / -1.19%
Volume 0.0
LSM On Other Exchanges
As of 2:08 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

lbt innovations ltd (LSM) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/8/15 - €0.08
52 Week Low
07/27/15 - €0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LBT INNOVATIONS LTD (LSM)

Related News

No related news articles were found.

lbt innovations ltd (LSM) Related Businessweek News

No Related Businessweek News Found

lbt innovations ltd (LSM) Details

LBT Innovations Limited researches and develops clinical and diagnostic technologies for the healthcare and laboratory supply markets in Australia, Switzerland, and the United States. It offers PREVI Isola, an automated streaking and inoculation system; and automated plate assessment system, which provides automation of culture plate streaking, a platform technology for the automation of culture-plate screening and interpretation. It has a licence agreement with bioMérieux; and technology licence agreement with Medvet Science Pty Ltd. The company was founded in 2004 and is based in Adelaide, Australia.

Founded in 2004

lbt innovations ltd (LSM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Managing...
Total Annual Compensation: A$315.0K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$75.0K
Vice President of Global Business Development
Total Annual Compensation: A$195.0K
Compensation as of Fiscal Year 2015.

lbt innovations ltd (LSM) Key Developments

LBT Innovations Limited Receives Successful Results from Pivotal Clinical Trial of its Pioneering Culture Plate Analysis Technology

LBT Innovations Limited has received successful results from a pivotal clinical trial of its pioneering culture plate analysis technology, the Automated Plate Assessment System (APAS®), at TriCore Reference Laboratories in the United States. The trial at the major medical laboratory in Albuquerque, New Mexico, tested the APAS technology against a panel of three microbiologists. The trial protocol and targets for the primary and secondary endpoints were set after consultation with the US Food and Drug Administration (FDA). The results showed that APAS achieved over 98% sensitivity in its detection of disease-causing bacteria on two of the most widely-used culture media -- Blood agar and MacConkey agar -- in urine samples from 5,500 patients. Blood agar and MacConkey agar are a standard two-plate protocol for culturing urine specimens in US laboratories. The Albuquerque trial analysed samples from this broad cohort of patients over 10 weeks between June and August 2015. Following incubation, the culture plates were processed by APAS and simultaneously assessed by a panel of three independent qualified microbiologists. The results of the APAS trial included: Greater than 98% sensitivity in the detection of microbial growth on blood agar, with a 95% confidence interval width in the order of 1%. The study successfully met the set target of 96%; Greater than 99% sensitivity in the detection of microbial growth on MacConkey agar, with a 95% confidence interval width in the order of 0.5%. The study successfully met the set target of 96%; Greater than 98% sensitivity in the detection of microbial growth for the whole sample, with a 95% confidence interval width of around 0.5%. The study successfully met the set target of 96%; Greater than 96% sensitivity for the segmentation of cases with microbial growth typical for urinary tract infections (UTIs), with a 95% confidence interval width in the order of 1%. The overall specificity was around 90%, and when there was no growth at all the specificity was around 98%; Greater than 98% sensitivity for the detection of microbial growth typical of E. coli, the cause of up to 86% of UTIs in the US and Europe. All of the primary endpoints were exceeded in the trial, which forms part of LBT's 510(k) de novo submission to the FDA. APAS achieved an overall sensitivity of more than 96% in its ability to combine the results from blood agar and MacConkey agar in assessing the presence of bacteria commonly associated with UTIs. The trial also achieved a number of secondary endpoints regarding APAS's differentiation and classification of clinical results, with important implications for the automated reporting and integration of patient results with laboratory and hospital information systems.

LBT Innovations Limited Reports Preliminary Earnings Results for the Year Ended June 30, 2015

LBT Innovations Limited reported preliminary earnings results for the year ended June 30, 2015. For the period, the company’s revenue was AUD 2.37 million, down from AUD 3.99 million a year ago. Loss before income tax was AUD 0.336 million against AUD 0.971 million a year ago. Profit for the year was AUD 0.321 million against AUD 0.292 million a year ago. Basic and diluted earnings per share was 0.28 cents against 0.29 cents a year ago. Net cash provided by operating activities was AUD 3.048 million against AUD 2.436 million a year ago. Payment for plant and equipment was AUD 0.035 million against AUD 0.072 million a year ago. Payment for research and development (intangible asset) was AUD 5.424 million against AUD 1.865 million a year ago. Revenue for the year ended June 30, 2015 decreased by 40.7% to AUD 2.37 million includes: AUD 1.00 million APAS final milestone bioMérieux royalty of AUD 0.846 million; grants income of AUD 0.310 million, revenue from APAS of AUD 0.076 million relating to a module prototype; and interest received of AUD 0.043 million. Net tangible assets per security was 2.2 cents per share as at June 30, 2015 against 2.6 cents per share as at June 30, 2014.

LBT Innovations Limited Announces Executive Changes

The Board of LBT Innovations Limited announced that Mr. Jamie Dreckow has resigned as Company Secretary and will be replaced by Mr. Daniel Hill, of whom is also currently LBT's Chief Financial Officer. Mr. Hill is a member of the ICAA, Fellow of FINSIA and a certificated member of the Governance Institute of Australia. Having worked in a range of industries, Mr. Hill has extensive experience in financial reporting and corporate governance.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LSM:GR €0.08 EUR -0.001

LSM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LSM.
View Industry Companies

Industry Analysis


Industry Average

Valuation LSM Industry Range
Price/Earnings 34.5x
Price/Sales 4.7x
Price/Book 0.7x
Price/Cash Flow 10.3x
TEV/Sales 3.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LBT INNOVATIONS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at